Merck Gets European Commission Approval of Capvaxive Vaccine

Published: 2025-03-26 07:10:15 ET MRK

By Colin Kellaher

Merck & Co. has won approval from the European Commission of its Capvaxive pneumococcal disease vaccine for adults.

The Rahway, N.J., drugmaker on Wednesday said the approval covers the 21-valent conjugate vaccine for immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 and older.

The U.S. Food and Drug Administration approved Capvaxive last June.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

03-26-25 0708ET